220 related articles for article (PubMed ID: 37067901)
1. Li-Fraumeni Syndrome-Associated Dimer-Forming Mutant p53 Promotes Transactivation-Independent Mitochondrial Cell Death.
Choe JH; Kawase T; Xu A; Guzman A; Obradovic AZ; Low-Calle AM; Alaghebandan B; Raghavan A; Long K; Hwang PM; Schiffman JD; Zhu Y; Zhao R; Lee DF; Katz C; Prives C
Cancer Discov; 2023 May; 13(5):1250-1273. PubMed ID: 37067901
[TBL] [Abstract][Full Text] [Related]
2. p53 Oligomerization Domain Mutants: A New Class of Mutants That Retain "License to Kill".
Stieg D; Casey K; Murphy ME
Cancer Discov; 2023 May; 13(5):1046-1048. PubMed ID: 37139723
[TBL] [Abstract][Full Text] [Related]
3. Dimeric p53 Mutant Elicits Unique Tumor-Suppressive Activities through an Altered Metabolic Program.
Gencel-Augusto J; Su X; Qi Y; Whitley EM; Pant V; Xiong S; Shah V; Lin J; Perez E; Fiorotto ML; Mahmud I; Jain AK; Lorenzi PL; Navin NE; Richie ER; Lozano G
Cancer Discov; 2023 May; 13(5):1230-1249. PubMed ID: 37067911
[TBL] [Abstract][Full Text] [Related]
4. Characterization of p53 oligomerization domain mutations isolated from Li-Fraumeni and Li-Fraumeni like family members.
Lomax ME; Barnes DM; Hupp TR; Picksley SM; Camplejohn RS
Oncogene; 1998 Aug; 17(5):643-9. PubMed ID: 9704930
[TBL] [Abstract][Full Text] [Related]
5. Oligomerization of Mutant p53 R273H is not Required for Gain-of-Function Chromatin Associated Activities.
Annor GK; Elshabassy N; Lundine D; Conde DG; Xiao G; Ellison V; Bargonetti J
Front Cell Dev Biol; 2021; 9():772315. PubMed ID: 34881245
[TBL] [Abstract][Full Text] [Related]
6. Mechanism of functional inactivation of a Li-Fraumeni syndrome p53 that has a mutation outside of the DNA-binding domain.
Gu J; Kawai H; Wiederschain D; Yuan ZM
Cancer Res; 2001 Feb; 61(4):1741-6. PubMed ID: 11245491
[TBL] [Abstract][Full Text] [Related]
7. Heterogeneity of Li-Fraumeni syndrome links to unequal gain-of-function effects of p53 mutations.
Xu J; Qian J; Hu Y; Wang J; Zhou X; Chen H; Fang JY
Sci Rep; 2014 Feb; 4():4223. PubMed ID: 24573247
[TBL] [Abstract][Full Text] [Related]
8. Analysis of genomic instability in Li-Fraumeni fibroblasts with germline p53 mutations.
Liu PK; Kraus E; Wu TA; Strong LC; Tainsky MA
Oncogene; 1996 Jun; 12(11):2267-78. PubMed ID: 8649766
[TBL] [Abstract][Full Text] [Related]
9. Characterization of the oligomerization defects of two p53 mutants found in families with Li-Fraumeni and Li-Fraumeni-like syndrome.
Davison TS; Yin P; Nie E; Kay C; Arrowsmith CH
Oncogene; 1998 Aug; 17(5):651-6. PubMed ID: 9704931
[TBL] [Abstract][Full Text] [Related]
10. A germline 2.35 kb deletion of p53 genomic DNA creating a specific loss of the oligomerization domain inherited in a Li-Fraumeni syndrome family.
Plummer SJ; Santibáñez-Koref M; Kurosaki T; Liao S; Noble B; Fain PR; Anton-Culver H; Casey G
Oncogene; 1994 Nov; 9(11):3273-80. PubMed ID: 7936651
[TBL] [Abstract][Full Text] [Related]
11. Reducing Fatty Acid Oxidation Improves Cancer-free Survival in a Mouse Model of Li-Fraumeni Syndrome.
Wang PY; Ma J; Li J; Starost MF; Wolfgang MJ; Singh K; Pirooznia M; Kang JG; Hwang PM
Cancer Prev Res (Phila); 2021 Jan; 14(1):31-40. PubMed ID: 32958587
[TBL] [Abstract][Full Text] [Related]
12. Dissociation between cell cycle arrest and apoptosis can occur in Li-Fraumeni cells heterozygous for p53 gene mutations.
Delia D; Goi K; Mizutani S; Yamada T; Aiello A; Fontanella E; Lamorte G; Iwata S; Ishioka C; Krajewski S; Reed JC; Pierotti MA
Oncogene; 1997 May; 14(18):2137-47. PubMed ID: 9174049
[TBL] [Abstract][Full Text] [Related]
13. Detection of both mutant and wild-type p53 protein in normal skin fibroblasts and demonstration of a shared 'second hit' on p53 in diverse tumors from a cancer-prone family with Li-Fraumeni syndrome.
Srivastava S; Tong YA; Devadas K; Zou ZQ; Sykes VW; Chen Y; Blattner WA; Pirollo K; Chang EH
Oncogene; 1992 May; 7(5):987-91. PubMed ID: 1373881
[TBL] [Abstract][Full Text] [Related]
14. p53 mutants G245S and R337H associated with the Li-Fraumeni syndrome regulate distinct metabolic pathways.
Meneghetti BV; Wilson R; Dias CK; Cadore NA; Klamt F; Zaha A; Ferreira HB; Monteiro KM
Biochimie; 2022 Jul; 198():141-154. PubMed ID: 35367578
[TBL] [Abstract][Full Text] [Related]
15. Inhibiting mitochondrial respiration prevents cancer in a mouse model of Li-Fraumeni syndrome.
Wang PY; Li J; Walcott FL; Kang JG; Starost MF; Talagala SL; Zhuang J; Park JH; Huffstutler RD; Bryla CM; Mai PL; Pollak M; Annunziata CM; Savage SA; Fojo AT; Hwang PM
J Clin Invest; 2017 Jan; 127(1):132-136. PubMed ID: 27869650
[TBL] [Abstract][Full Text] [Related]
16. Functional studies of a novel germline p53 splicing mutation identified in a patient with Li-Fraumeni-like syndrome.
Piao J; Sakurai N; Iwamoto S; Nishioka J; Nakatani K; Komada Y; Mizutani S; Takagi M
Mol Carcinog; 2013 Oct; 52(10):770-6. PubMed ID: 22495821
[TBL] [Abstract][Full Text] [Related]
17. Tissue-specific expression of SV40 in tumors associated with the Li-Fraumeni syndrome.
Malkin D; Chilton-MacNeill S; Meister LA; Sexsmith E; Diller L; Garcea RL
Oncogene; 2001 Jul; 20(33):4441-9. PubMed ID: 11494139
[TBL] [Abstract][Full Text] [Related]
18. Divergent control of Cav-1 expression in non-cancerous Li-Fraumeni syndrome and human cancer cell lines.
Sherif ZA; Sultan AS
Cancer Biol Ther; 2013 Jan; 14(1):29-38. PubMed ID: 23114650
[TBL] [Abstract][Full Text] [Related]
19. Leukemic and non-leukemic lymphocytes from patients with Li Fraumeni syndrome demonstrate loss of p53 function, Bcl-2 family dysregulation and intrinsic resistance to conventional chemotherapeutic drugs but not flavopiridol.
Pepper C; Thomas A; Hoy T; Tighe J; Culligan D; Fegan C; Bentley P
Cell Cycle; 2003; 2(1):53-8. PubMed ID: 12695689
[TBL] [Abstract][Full Text] [Related]
20. Allele-specific wild-type TP53 expression in the unaffected carrier parent of children with Li-Fraumeni syndrome.
Buzby JS; Williams SA; Schaffer L; Head SR; Nugent DJ
Cancer Genet; 2017 Feb; 211():9-17. PubMed ID: 28279309
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]